SQLite Web: event_store.db

Update row 128718 in events

seq

Primary key. INTEGER

id

TEXT NOT NULL

kind

TEXT NOT NULL

ts

TEXT NOT NULL

actor

TEXT

subject_entity_ids

TEXT

payload

{"created_at":"2026-04-18T03:05:05.644967+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:b5301901908fefd8","evidence_event_ids":["evt_50ee6915ada1"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1590750/0001193125-26-160344.txt","as_of":"2026-04-18T03:05:05.644967+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1590750/0001193125-26-160344.txt","company":"Viridian Therapeutics, Inc.\\DE","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1590750/0001193125-26-160344.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_5849504e97dea372","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1590750/0001193125-26-160344.txt","content_type":"text/plain","enriched_at":"2026-04-18T03:19:54.927634+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"DEF 14A","final_url":"https://www.sec.gov/Archives/edgar/data/1590750/0001193125-26-160344.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1590750/0001193125-26-160344.txt","source_event_id":"evt_50ee6915ada1","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"DEF 14A","fp":"0cef2a1870985d58","kind":"sec_filing","published_at":"20260417","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-06-02","2026-04-07","2026-04-17","2026-04-18"],"entities":[{"asset_class":"equity","name":"Viridian Therapeutics, Inc.","relevance":"high","symbol":"VRDN","type":"issuer"},{"asset_class":"other","name":"U.S. Securities and Exchange Commission (SEC)","relevance":"medium","symbol":"","type":"regulator"},{"asset_class":"other","name":"VirtualShareholderMeeting.com","relevance":"low","symbol":"","type":"meeting_platform"}],"event_type":"listing","information_gaps":["The specific proposals/items included in the proxy statement are not present in the provided text excerpt (e.g., director nominees, voting matters).","The excerpt does not describe any changes versus a prior known state beyond the fact that this DEF 14A was filed.","No details are provided about executive compensation or equity compensation utilization beyond general forward-looking statement language."],"key_facts":["Form DEF 14A is a proxy statement for Viridian Therapeutics, Inc. (the \u201cCompany\u201d).","The 2026 Annual Meeting of Stockholders will be held on Tuesday, June 2, 2026 at 2:00 p.m. Eastern Time.","The Annual Meeting will be a virtual meeting conducted exclusively online via live audio webcast at www.virtualshareholdermeeting.com/VRDN2026.","The Board fixed April 7, 2026 as the record date.","Only stockholders of record at the close of business on April 7, 2026 are entitled to notice of, and to vote at, the Annual Meeting (and any adjournment or postponement).","The proxy materials are first being made available to stockholders on or about April 17, 2026.","The proxy materials are furnished primarily via the internet pursuant to SEC rules (instead of mailing printed copies)."],"numeric_claims":[{"label":"Annual Meeting date","value":"2026-06-02"},{"label":"Annual Meeting time (ET)","value":"2:00 p.m."},{"label":"Record date","value":"2026-04-07"},{"label":"Proxy materials availability date (approx.)","value":"2026-04-17"}],"primary_claim":"Viridian Therapeutics, Inc. filed Form DEF 14A for its 2026 Annual Meeting of Stockholders, scheduled for June 2, 2026 (virtual) with a record date of April 7, 2026.","relevance_score":0.55,"sentiment":"neutral","source_quality":"high","summary":"Viridian Therapeutics, Inc. filed a DEF 14A proxy statement for its 2026 Annual Meeting of Stockholders. The filing states the meeting will be held virtually on June 2, 2026, with April 7, 2026 as the record date.","topics":["SEC filing","DEF 14A","proxy statement","annual meeting","virtual meeting","record date","stockholder voting"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form DEF 14A \u00b7 Viridian Therapeutics, Inc.\\DE \u00b7 Filed 20260417","ticker":"VRDN","tickers":["VRDN"],"title":"VRDN filed DEF 14A","url":"https://www.sec.gov/Archives/edgar/data/1590750/0001193125-26-160344.txt"}}

TEXT NOT NULL

source_ref

TEXT

confidence

REAL (default 0.0

dedupe_key

TEXT

episode_id

TEXT

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel